Declan Doogan M.D.
Chairman and Director
Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the USA, UK and Japan. Dr. Doogan was the clinical development head for what was to become ZOLOFT, an important antidepressant and one of…
Eric Aguiar M.D
Dr. Aguiar is a partner at Aisling Capital and previously was a partner at Thomas, McNerney and Partners, a $600 million health care focused venture capital and growth equity fund, from 2007-2015. Eric was a Managing Director of HealthCare Ventures, a health care venture capital fund, from 2001-2007. Eric currently sits on the board of Invitae Corporation, a NYSE listed company…
Gregory H. Bailey, M.D.
Dr. Bailey has spent the last fifteen years as an entrepreneur, executive and financier in the health care sector. He is currently Chairman of the Board at Portage Biotech Inc. and has served on the Board of Directors for 16 public companies. He is a former director and financier of Medivation Inc. (MDVN: NASDAQ) and co-founder of Ascent Healthcare Solutions, VirnetX Inc internet security (VHC: AMEX) and Duramedic Inc., a medical…
John W. Childs
Mr. John W. Childs serves as the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm. He co-founded J.W. Childs Associates in 1995. Prior to founding J.W. Childs Associates, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995. In this capacity, he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions for the THL funds.
Vlad Coric, M.D.
Chief Executive Office and Director
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma.
Julia P. Gregory, M.B.A.
Ms. Gregory formerly served as President and CEO of Five Prime Therapeutics, Inc. from 2009 until July 2012, and as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. from 2000 to 2008…